Trade GTBP stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
GT Biopharma, Inc. (GTBP) is trading at US$6.68, up 12.08% today as of Oct 9, 16:00 EDT. The company has a market capitalisation of US$13.02M. Over the past 52 weeks, GTBP has traded between US$4.91 and US$28.75. On Syfe you can trade GTBP with $0 commission and add it to your watchlist.
| Previous close | US$5.96 |
|---|---|
| Market cap | US$13.02M |
| 52-week range | US$4.91 – US$28.75 |
| Volume | 42.4K |
| Exchange | US |
GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary TriKE and Dual Targeting TriKE platforms. Its product candidates include GTB-3650, a CD33-targeted therapy for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, and GTB-5550, a B7-H3-targeted therapy for solid tumors. The company was founded in 1965 and is headquartered in San Francisco, CA.
Year: 2021
GT Biopharma, Inc. (GTBP) stock is trading at US$6.68, +12.08% from the previous close of US$5.96.
The market cap for GT Biopharma, Inc. (GTBP) stock is approximately US$13.02M.
The 52-week high for GT Biopharma, Inc. (GTBP) stock is US$28.75.
The 52-week low for GT Biopharma, Inc. (GTBP) stock is US$4.91.
GT Biopharma, Inc. (GTBP) does not currently pay a dividend.
Stay on top of GTBP
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
